Evidence map›Paper›PMID 37864216›Full record

ArticleBMC medicine2023

Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank.

Yu Jia, Dongze Li, Yi You, Jing Yu, Wenli Jiang, Yi Liu, Rui Zeng, Zhi Wan, Yi Lei, Xiaoyang Liao

Abstract read
In one paragraph

Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. [Predictive value of a Chinese visceral adiposity index for metabolic associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu JiaGeneral Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, 37 Guoxue Road, Chengdu, 610041, China.
Dongze LiDepartment of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yi YouSchool of Computer Science, Sichuan University, Chengdu, Sichuan, China.
Jing YuDepartment of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wenli JiangGeneral Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, 37 Guoxue Road, Chengdu, 610041, China.
Yi LiuDepartment of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Rui ZengDepartment of Cardiology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Zhi WanDepartment of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yi LeiGeneral Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, 37 Guoxue Road, Chengdu, 610041, China. leiyi111@scu.edu.cn.
Xiaoyang LiaoGeneral Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, 37 Guoxue Road, Chengdu, 610041, China. liaoxiaoyang@wchscu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification.

methodsAfter propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections.

resultsParticipants aged 59 (51-64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid-base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results.

conclusionsIndividuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD.

Indexed as

ArthritisAsthmaNon-alcoholic Fatty Liver DiseaseBiological Specimen BanksFemaleHumansMaleUnited KingdomDisease trajectoryMetabolic dysfunction-associated fatty liver diseaseMortalityNonalcoholic fatty liver disease

Identifiers

PMID37864216
PMCPMC10590000

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.